- Altos Labs – a $3 billion biotech startup backed by Jeff Bezos – is on a mission to restore cell health and reverse diseases by rejuvenating cells . It launched in 2022 with a dream of extending healthy human lifespan.
- Not about “cheating death”: Altos’s president Hans Bishop insists the focus is on extending “healthspan” (years of healthy life), with any longevity gains merely an “accidental consequence” fightaging.org. The company emphasizes improving life quality over pursuing immortality.
- Unprecedented talent & funding: Altos assembled a “dream team” of scientists – including Nobel laureate Shinya Yamanaka – by offering academic freedom and industry-level resources. Led by former GSK executive Hal Barron as CEO, and co-founded by biotech veterans Richard Klausner and Hans Bishop, Altos attracted $3 billion from prominent investors (Bezos, Yuri Milner, Arch Ventures) labiotech.eu en.wikipedia.org, making it one of the best-funded startups in biotech history.
- Racing a booming longevity industry: Altos Labs is part of a broader anti-aging biotech boom. Alphabet’s Calico Labs (launched 2013) was a pioneer, and newer startups like Retro Biosciences and Loyal have joined the fray – all aiming to extend healthy lifespan via cutting-edge science and drawing investments from Silicon Valley billionaires .
- Innovations in “rejuvenation” science: Altos and its peers are leveraging breakthroughs like partial cellular reprogramming – using Yamanaka factors to reset adult cells to a youthful state – which has shown promise in animals labiotech.eu labiotech.eu. Other approaches include senolytic drugs to clear aged “zombie” cells and gene therapies, all targeting aging at its biological roots.
- Early results signal hope: In 2024, Altos scientists published a landmark study demonstrating that partial reprogramming extended the lifespan of mice and improved health markers . This evidence that aging may be reversible has been hailed as a major step toward translating rejuvenation technologies to humans.
- Competition and collaboration: Companies like Retro Biosciences (funded by OpenAI’s Sam Altman) aim to add 10+ years to human life through cell reprogramming and autophagy, planning their first clinical trials and reportedly seeking $1 billion for next steps . Loyal, which has raised over $125 million, is developing drugs to extend dogs’ lifespans as a springboard to human applications – and expects to launch the first FDA-approved longevity drug for pets by 2025
Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging
Latest articles
Klaviyo Stock Holds Near Lows; Direction Awaits Key Decision
Klaviyo closed Tuesday at $14.70, up 0.6%, but remained near its 52-week low after a sharp post-earnings drop. A May 18 Form 144 notice signaled potential insider sales. Shares were down about 27% in the past month and 57% over the year, with a market value near $4.4 billion. First-quarter revenue rose 28% to $358 million, but growth is forecast to slow.
Chewy Shares Slide on CEO Talk of “Stretched Consumer”
Chewy Inc. shares dropped 9.1% to $19.66 Tuesday after CEO Sumit Singh warned U.S. consumers are more financially strained than earlier this year. The decline put Chewy near its 52-week low ahead of its June 10 earnings report. Singh made the comments at a J.P. Morgan conference, citing multiple data points on weaker consumer demand. Petco fell 2.9%, while BARK rose 7.5% and Amazon slipped 2.1%.
Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now
Meiwu Technology shares jumped 97% to $4.75 Tuesday and rose another 12% premarket after the company raised $15.65 million in a private share sale to fund an AI skincare platform. The rally follows a 1-for-100 reverse share split in April and earlier $14 million direct offering. Meiwu warned its new platform is early-stage and faces regulatory risks.
